China-based Yabao Pharmaceutical has entered into an exclusive license with MRC Technology, a UK-based medical research charity, to discover, develop and commercialise new products targeting a kinase target for neurodegeneration to treat Parkinson's disease.
As part of the deal, Yabao will receive exclusive rights to discover, develop and commercialise new products in China, Taiwan and Hong Kong, while MRC Technology will retain rights in all other markets.
Yabao Pharmaceutical president R&D Dr Peng Wang said: "Yabao is pleased to be collaborating with MRC Technology, a leading UK research institute focused on improving the lives of patients through medical discovery.
"This opportunity for Yabao to expand on leading research to develop innovative products is further evidence of Yabao's growing commitment to partner the best science to treat serious diseases in China."
The collaboration is aimed at bringing new treatments to patients and improve their quality of life.
MRC Technology director of Business Development Michael Dalrymple said: "Parkinson's is a debilitating and destructive disease.
"We are pleased to combine our expertise in early drug discovery and innovation with the significant resources that Yabao Pharmaceutical Co. can bring to developing ground breaking new medicines."
MRC Technology provides professional services to organisations within the academic, charity, biotechnology and pharmaceutical sectors across the world.
http://health.einnews.com/article/236251712/CG50O9WCxDo79GuP?n=2&code=ga_qGBxHZ2aVYO4P
No comments:
Post a Comment